丁辛耘

[摘要] 目的 探究西格列汀與二甲雙胍同用對2型糖尿病患者血糖指標水平及療效的影響。方法 將2018年11月—2019年11月該院收治的148例2型糖尿病患者隨機分為對照組與試驗組，每組74例，對照組以二甲雙胍治療，試驗組在對照組基礎上加用西格列汀治療;比較兩組治療前后空腹血糖、餐后2 h血糖、糖化血紅蛋白水平，比較兩組臨床療效與不良反應發(fā)生率。結果 治療后，兩組空腹血糖等上述指標水平均較治療前顯著下降（P<0.05），且試驗組顯著低于對照組（P<0.05）;試驗組有效率91.89%顯著高于對照組79.73%，（P<0.05）;兩組不良反應發(fā)生率差異無統(tǒng)計學意義（P>0.05）。結論 西格列汀與二甲雙胍同用治療2型糖尿病可顯著降低患者空腹血糖等多項血糖指標水平、提高臨床療效且安全可靠。

[關鍵詞] 2型糖尿病;西格列汀;二甲雙胍;空腹血糖;餐后2 h血糖;糖化紅蛋白

[中圖分類號] R587.1? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1672-4062（2020）09（b）-0066-03

Explore the Effects of Sitagliptin and Metformin on Blood Glucose Levels and Curative Effects in Patients with Type 2 Diabetes

DING Xin-yun

Department of Internal Medicine， Shanghai Hudong Hospital， Shanghai， 200129 China

[Abstract] Objective To explore the effect of sitagliptin and metformin on blood glucose levels and curative effects in patients with type 2 diabetes. Methods 148 patients with type 2 diabetes admitted to the hospital from November 2018 to November 2019 were randomly divided into a control group and a test group， 74 cases in each group. The control group was treated with metformin， and the test group was added sitagliptin treatment; compare the fasting blood glucose before and after treatment， 2 h postprandial blood glucose， and glycosylated hemoglobin levels between the two groups， and compare the clinical efficacy and the incidence of adverse reactions between the two groups. Results After treatment， the levels of the above indicators such as fasting blood glucose in the two groups were significantly lower than before treatment（P<0.05）， and the experimental group was significantly lower than the control group （P<0.05）; the effective rate of the experimental group 91.89% was significant， higher than the control group 79.73%（P<0.05）; there was no statistically significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion The simultaneous use of sitagliptin and metformin in the treatment of type 2 diabetes can significantly reduce the fasting blood glucose and other blood glucose indicators， improve the clinical efficacy， and is safe and reliable.

[Key words] Type 2 diabetes; Sitagliptin; Metformin; Fasting blood glucose; 2 h postprandial blood glucose; Glycosylated globin

糖尿病是臨床常見的慢性代謝性疾病，在糖尿病患者中2型糖尿病所占比重高達90%，高血糖為該病主要臨床特征，一般情況下，高血糖多由胰島素分泌缺陷與胰島素抵抗所致。患者常常由于血糖增高引起血管、眼、神經(jīng)等機體多處組織、器官功能障礙，嚴重時引起電解質紊亂、酸堿失衡甚至酸中毒和高滲昏迷等，嚴重危害患者生命健康，影響其生活質量[1-2]。調(diào)節(jié)血糖仍是治療糖尿病的首要目標，臨床上通常以飲食調(diào)節(jié)、增強運動、服用降糖藥等多種途徑治療[3]。雖然治療途徑多樣，但大部分患者仍難將血糖下調(diào)至理想狀態(tài)，因此，尋找更安全有效的治療方法乃治療該病的關鍵任務。二甲雙胍為臨床常用降糖藥，該藥在糖尿病治療中，短期療效顯著，長期的血糖控制效果尚不理想;西格列汀是近年新研發(fā)的新型降糖藥，該藥可通過增強長促胰島激素活性，使胰島素分泌量增加，進而實現(xiàn)對胰島素的調(diào)節(jié)與控制。該次研究將以二者聯(lián)合治療2018年11月—2019年11月至該院就診的148例2型糖尿病患者，以觀二者聯(lián)用對患者血糖指標水平及臨床療效的影響，現(xiàn)報道如下。